Mirum Pharmaceuticals said it will host an investor call on May 4, 2026 to report topline Phase 2b VISTAS trial results for Volixibat in primary sclerosing cholangitis. The update is a scheduled clinical readout rather than a data release, so the near-term impact is likely limited unless results materially surprise. No trial outcomes or financial figures were disclosed in the article.
Mirum Pharmaceuticals said it will host an investor call on May 4, 2026 to report topline Phase 2b VISTAS trial results for Volixibat in primary sclerosing cholangitis. The update is a scheduled clinical readout rather than a data release, so the near-term impact is likely limited unless results materially surprise. No trial outcomes or financial figures were disclosed in the article.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
